News

First head-to-head trial compares tirzepatide and semaglutide - Results are in!
Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight ...
Technology Networks2d
Zepbound Outcompetes Wegovy for Weight Loss in Head-to-Head Trials
Tirzepatide promoted greater weight loss in individuals with obesity than semaglutide in a clinical trial that compared the ...
Victoria Advocate5d
Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study
Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...
Today5d
Is Zepbound or Wegovy better for weight loss? First-of-its-kind study offers answer
A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...
Atlanta Journal-Constitution6d
Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...
Wall Street Journal5d
Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy
Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.